The University of Texas Health Science Center at Houston is a comprehensive academic health center created in 1972 by The UT System Board of Regents. UTHealth is located in the Texas Medical Center, considered the largest medical center in the world. It is composed of six schools: UTHealth Medical School, The University of Texas Graduate School of Biomedical science, UTHealth School of Dentistry, UTHealth School of Nursing, UTHealth School of Biomedical Informatics, and UTHealth School of Public Health. UTHealth faculty have been instrumental in pioneering the use of Tissue plasminogen activator and the development of Life Flight. Wikipedia.
News Article | May 26, 2017
Faced with a barrage of criticism, the National Institutes of Health (NIH) has scaled back a plan to cap its support for individual labs in order to free up funds for more scientists. The changes did not appease scientists who gave NIH a tongue-lashing this morning at a meeting of NIH’s Council of Councils. Council member Jonathan Epstein described the “serious concerns” about the policy as “more than I’ve ever seen before in my scientific career.” He came close to resigning in protest because NIH did not consult the council first, said Epstein, who is chief scientific officer and executive vice dean at the University of Pennsylvania School of Medicine in Philadelphia. Many researchers “feel that this was thrust upon them,” he added. The policy announced on 2 May would assign points to various types of grants and give individual investigators a total score called a Grant Support Index (GSI). NIH would aim to limit a person’s GSI to 21 points, or the equivalent of three standard R01 grants. The objective, NIH explained, is to free up funds now held by 6% of the 1950 lead investigators over the cap so that NIH could support 1600 more grants for early- and midcareer investigators. Many worry, however, that this plan would pare back highly productive labs and discourage collaborations, among other concerns. In response to more than 360 online comments and many letters from individuals and scientific societies, some supportive and others critical—NIH is tweaking its analysis practically ”every single day,” said NIH extramural research chief Mike Lauer at today’s council meeting. For example, NIH is now excluding training grants, clinical trial networks, and infrastructure awards from the GSI and has lowered the points for a multi-investigator R01 from 6 to 5. After these revisions, just 3% of investigators are over the cap, and the number of additional grants that could be funded has shrunk to 900, according to Lauer’s presentation. Those changes didn’t satisfy some council members. Epstein said the plan has caused “serious concerns” among the 70 investigators at the University of Pennsylvania at or above the (original) GSI cap. He said that as a result, faculty have abandoned plans for at least two collaborations; he is pleading with two others who are considering a move overseas to stay. He urged NIH to put a hold on the policy, which is to be implemented starting in the fall. Eric Boerwinkle of the University of Texas Health Science Center at Houston called the policy “rushed out” and said it “has caused enormous anxiety.” And Paul Johnson, director of Emory University’s Yerkes Primate Research Center in Atlanta, worried that it will “have a devastating effect on our ability to do collaborative science” in areas such as AIDS vaccine development. Lauer defended the policy as “a leadership decision” that follows years of discussions at NIH. He also put some blame on Congress: during negotiations over the 21st Century Cures Act that provides $4.8 billion in new NIH funding over 10 years, lawmakers expressed concerns that “too much of [NIH’s] money is being concentrated in certain places,” Lauer said. Some scientists have also questioned an NIH analysis underpinning the policy that finds that as investigators’ GSI rises about 21 (or three R01 grants), their increase in productivity begins to taper. (One such critique was posted on Medium earlier this week.) Today, NIH posted an online preprint and supplemental materials for that analysis.
Cao B.,University of Texas Health Science Center at Houston
Neuropsychopharmacology | Year: 2017
Previous studies have found increased levels of choline-containing compounds (ie, glycerophosphocholine plus phosphocholine (GPC+PC)) in bipolar disorder using in vivo proton magnetic resonance spectroscopy (1H MRS), especially in bipolar I disorder (BD-I). Increased levels of GPC+PC suggest alterations in the membrane phospholipids metabolism in bipolar disorder. Rapid cycling (RC) bipolar disorder is considered as a severe course of bipolar disorder, but it is unclear whether rapid cycling bipolar disorder is linked to highly altered membrane phospholipid metabolism. The purpose of this study was to investigate whether the regional extent of elevated GPC+PC were greater in BD-I patients with rapid cycling compared to BD-I patients without rapid cycling and healthy controls. Using a multi-voxel 1H MRS approach at 3 Tesla with high spatial resolution and absolute quantification, GPC+PC levels from the anterior cingulate cortex (ACC), caudate and putamen of 16 RC BD-I, 34 non-RC BD-I and 44 healthy controls were assessed. We found significantly elevated GPC+PC levels in ACC, putamen and caudate of RC BD-I patients compared to healthy controls (P<0.005) and in ACC compared to non-RC BD-I patients (P<0.05). These results suggest greater alteration of membrane phospholipid metabolisms in rapid cycling BD-I compared to non-rapid-cycling BD-I.Neuropsychopharmacology advance online publication, 29 March 2017; doi:10.1038/npp.2017.39. © 2017 American College of Neuropsychopharmacology
Reubi J.C.,University of Bern |
Schonbrunn A.,University of Texas Health Science Center at Houston
Trends in Pharmacological Sciences | Year: 2013
Somatostatin analogs for the diagnosis and therapy of neuroendocrine tumors (NETs) have been used in clinical applications for more than two decades. Five somatostatin receptor subtypes have been identified and molecular mechanisms of somatostatin receptor signaling and regulation have been elucidated. These advances increased understanding of the biological role of each somatostatin receptor subtype, their distribution in NETs, as well as agonist-specific regulation of receptor signaling, internalization, and phosphorylation, particularly for the sst2 receptor subtype, which is the primary target of current somatostatin analog therapy for NETs. Various hypotheses exist to explain differences in patient responsiveness to somatostatin analog inhibition of tumor secretion and growth as well as differences in the development of tumor resistance to therapy. In addition, we now have a better understanding of the action of both first generation (octreotide, lanreotide, Octreoscan) and second generation (pasireotide) FDA-approved somatostatin analogs, including the biased agonistic character of some agonists. The increased understanding of somatostatin receptor pharmacology provides new opportunities to design more sophisticated assays to aid the future development of somatostatin analogs with increased efficacy. © 2013 Elsevier Ltd. All rights reserved.
Gonzalez-Burgos G.,University of Pittsburgh |
Cho R.Y.,University of Texas Health Science Center at Houston |
Lewis D.A.,University of Pittsburgh
Biological Psychiatry | Year: 2015
Cognitive deficits are a core clinical feature of schizophrenia but respond poorly to available medications. Thus, understanding the neural basis of these deficits is crucial for the development of new therapeutic interventions. The types of cognitive processes affected in schizophrenia are thought to depend on the precisely timed transmission of information in cortical regions via synchronous oscillations at gamma band frequency. Here, we review 1) data from clinical studies suggesting that induction of frontal cortex gamma oscillations during tasks that engage cognitive or complex perceptual functions is attenuated in schizophrenia; 2) findings from basic neuroscience studies highlighting the features of parvalbumin-positive interneurons that are critical for gamma oscillation production; and 3) results from recent postmortem human brain studies providing additional molecular bases for parvalbumin-positive interneuron alterations in prefrontal cortical circuitry in schizophrenia. © 2015 Society of Biological Psychiatry.
Okusaga O.O.,University of Texas Health Science Center at Houston
Aging and Disease | Year: 2014
Several lines of evidence suggest that schizophrenia, a severe mental illness characterized by delusions, hallucinations and thought disorder is associated with accelerated aging. The free radical (oxidative stress) theory of aging assumes that aging occurs as a result of damage to cell constituents and connective tissues by free radicals arising from oxygen-associated reactions. Schizophrenia has been associated with oxidative stress and chronic inflammation, both of which also appear to reciprocally induce each other in a positive feedback manner. The buildup of damaged macromolecules due to increased oxidative stress and failure of protein repair and maintenance systems is an indicator of aging both at the cellular and organismal level. When compared with age-matched healthy controls, schizophrenia patients have higher levels of markers of oxidative cellular damage such as protein carbonyls, products of lipid peroxidation and DNA hydroxylation. Potential confounders such as antipsychotic medication, smoking, socio-economic status and unhealthy lifestyle make it impossible to solely attribute the earlier onset of aging-related changes or oxidative stress to having a diagnosis of schizophrenia. Regardless of whether oxidative stress can be attributed solely to a diagnosis of schizophrenia or whether it is due to other factors associated with schizophrenia, the available evidence is in support of increased oxidative stress-induced cellular damage of macromolecules which may play a role in the phenomenon of accelerated aging presumed to be associated with schizophrenia.
Sevick-Muraca E.M.,University of Texas Health Science Center at Houston
Annual Review of Medicine | Year: 2012
Technical developments in near-infrared fluorescence (NIRF) imaging and tomography have enabled recent translation into investigational human studies. Noninvasive imaging of the lymphatic vasculature for diagnosis and assessment of function has been uniquely accomplished with NIR using indocyanine green (ICG), a nonspecific dye that has comparatively poor fluorescent properties compared to emerging dyes. Adjunct use of NIRF-ICG for (a) intraoperative sentinel lymph node mapping for cancer staging, (b) video-angiography during surgery, and (c) discrimination of malignant from benign breast lesions detected by mammography and ultrasongraphy also evidences the clinical utility of NIRF. Future NIRF imaging agents that consist of bright fluorescent dyes conjugated to disease-targeting moieties promise molecular imaging and image-guided surgery. In this review, emerging NIRF imaging is described within the context of nuclear imaging technologies that remain the "gold standard" of molecular imaging. © 2012 by Annual Reviews. All rights reserved.
Reveille J.D.,University of Texas Health Science Center at Houston
Nature Reviews Rheumatology | Year: 2012
Ankylosing spondylitis (AS), psoriasis and inflammatory bowel disease (IBD) often coexist in the same patient and in their families. In AS, genes within the MHC region, in particular HLA-B27, account for nearly 25% of disease hereditability, with additional small contributions from genes outside of the MHC locus, including those involved in intracellular antigen processing (that is, ERAP1, which interacts with HLA-B27) and cytokine genes such as those involved in the IL-17-IL-23 pathway. Similar to AS, the strongest genetic signal of susceptibility to psoriasis and psoriatic arthritis also emanates from the MHC region (attributable mostly to HLA-C * 06:02 although other genes have been implicated), and gene-gene interaction of HLA-C with ERAP1. The remaining hereditary load is from genes involved in cytokine production, specifically genes in the IL-17-IL-23 pathway, the NFκB pathway and the type 2 T-helper pathway. In IBD, similar genetic influences are operative. Indeed, genes important in the regulation of the IL-17-IL-23 pathway and, in Crohn's disease, genes important for autophagy (that is, NOD2 and ATG16L1 and IRGM) have a role in conferring susceptibility of individuals to these diseases. Thus, AS, psoriasis and IBD seem to share similar pathogenic mechanisms of aberrant intracellular antigen processing or elimination of intracellular bacteria and cytokine production, especially in the IL-17-IL-23 pathway. © 2012 Macmillan Publishers Limited All rights reserved.
Wu T.-C.,University of Texas Health Science Center at Houston |
Grotta J.C.,University of Texas Health Science Center at Houston
The Lancet Neurology | Year: 2013
Ischaemic stroke is one of the leading causes of death and disability worldwide, and intravenous alteplase is the only proven effective treatment in the acute setting. Hypothermia has been shown to improve neurological outcomes after global ischaemia-hypoxia in comatose patients who have had cardiac arrest, and is one of the most extensively studied and powerful therapeutic strategies in acute ischaemic stroke. The protective mechanisms of therapeutic hypothermia affect the ischaemic cascade across several parallel pathways and, when coupled with reperfusion strategies, might yield synergistic benefits for patients who have had a stroke. Technological advances have allowed hypothermia to be induced rapidly, and the treatment has been used safely in acute stroke patients. Conclusive efficacy trials assessing therapeutic hypothermia combined with reperfusion therapies in acute ischaemic stroke are ongoing. © 2013 Elsevier Ltd.
Agency: NSF | Branch: Standard Grant | Program: | Phase: CDS&E-MSS | Award Amount: 138.00K | Year: 2016
This project aims to develop a system of statistical analysis tools to tackle several important challenges in analysis of complex bioinformatics data, which involves a variety of response variables and tens of thousands independent variables. The interest often lies in identifying the key independent variables associated with the response variables, and understanding such associations as well as the interactions among the independent variables.
The extreme magnitude and complexity of bioinformatics data have posed serious challenges for data analysis. To overcome these challenges, we propose (i) to systematically and properly integrate multi-scale data before we can apply our novel modeling and analysis methods since the data we explore are collected by numerous independent studies at phenotypic, cellular, protein, and genetic levels with information from very different time and dimension scales; (ii) to develop feature screening criteria for a mixed type of longitudinal data using the combination of correlation tests in bivariate longitudinal regression models and the Benjamini-Hochberg-Yekutieli procedure, (iii) to develop graphical models that allow the variables being a mix of continuous and discrete longitudinal variables, with the nodes representing variables and each edge indicating the dependence of the two relevant variables conditional on the other variables; and (iv) to investigate the functioning form of each predictor by resorting to the data themselves under the framework of a mixed effects regression model with a continuous or discrete response and a high dimensional vector of predictors, with the resulting procedure allowing a user to simultaneously determine the form of each predictor effect to be zero, linear or nonlinear.
Agency: NSF | Branch: Standard Grant | Program: | Phase: | Award Amount: 249.29K | Year: 2016
IIS-1637347 Increasing Healthcare Access to At-Risk Populations:Research-based Policies for Mobile Health Clinics Project Description
Mobile clinics play an important role in providing healthcare to at-risk populations in both urban and rural areas. Currently, over 1500 mobile clinics operate in the US and handle over 5 million visits per year providing essential healthcare services. These programs, however, have grown organically over time and it is important to establish evidence-based approaches to encourage a systematic expansion of this essential healthcare delivery model. This proposal addresses this issue through the use of epidemiological and economic GIS data, combined with proprietary routing software, to implement a program for optimal delivery of mobile clinic healthcare services in the Houston, Texas, region. The project involves eight different providers and includes designing systematic strategies for meeting future healthcare needs of low-income communities. The aim is also to develop models and techniques that can be implemented by mobile clinic programs throughout the country. Early estimates indicate that this project can result in 20% increase in mobile health clinic capacity, which could translate into significant savings in healthcare costs, and considerable improvements in quality of life for the poor. These results are in line with the NSF mission goal of promoting the advancement of health.
The overall goal of this project is to optimize and implement a data-based program for coordinated deployment of mobile clinic programs. We will initially identify optimal expansion strategies for the eight current mobile clinics programs to meet the fast-growing demand for healthcare services in underserved communities. The project will then measure the potential of the developed models and techniques and apply them to mobile clinic programs in other regions of Texas and other states in the nation. To achieve the above goals, the team will first apply data mining and forecasting techniques to estimate present and future demand of healthcare services in selected communities. We will combine these approaches with advance GIS mapping tools and stochastic measures to identify target population clusters. We will also conduct survey and economic analysis to measure the operational cost and identify operational constraints in the present mobile clinic programs, and develop new optimization models for the deployment of the mobile clinic service. Then, we will develop new effective techniques to solve the developed optimization models to estimate the maximum capacity of the current mobile health clinic programs in the Houston region, and identify expansion strategies to meet the future service demand while minimizing cost. Lastly, we will estimate overall healthcare cost savings and quality of life impact at the community level at baseline and post-intervention.